Kinetics of 5-HT2B Receptor Signaling: Profound Agonist-Dependent Effects on Signaling Onset and Duration

Journal of Pharmacology and Experimental Therapeutics

Volumn 347, Issue 3, 2013, Pages 645-659

  Unett, David J ^a   Gatlin, Joel ^a   Anthony, Todd L ^a   Buzard, Daniel J ^a   Chang, Steve ^a   Chen, Chuan ^a   Chen, Xiaohua ^a   Dang, Huong T M ^a   Frazer, John ^a   Le, Minh K ^a   Sadeque, Abu J M ^a   Xing, Charles ^a   Gaidarov, Ibragim ^a  

^a ARENA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 5 METHOXY 3 (1,2,3,6 TETRAHYDRO 4 PYRIDYL) 1H INDOLE; 6 CHLORO 2 (1 PIPERAZINYL)PYRAZINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8,9 DICHLORO 2,3,4,4A TETRAHYDRO 1H PYRAZINO[1,2 A]QUINOXALIN 5(6H) ONE; BETA ARRESTIN; CABERGOLINE; CALCIUM ION; DIHYDROERGOTAMINE; ERGOMETRINE; ERGOT DERIVATIVE; ERGOTAMINE; FENOLDOPAM; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INOSITOL PHOSPHATE; LORCASERIN; METHYLERGOMETRINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NORFENFLURAMINE; PERGOLIDE; PHENOXYBENZAMINE; PHOSPHOLIPASE C; QUIPAZINE; SEROTONIN; SEROTONIN 2B RECEPTOR; SEROTONIN 2B RECEPTOR AGONIST; SEROTONIN AGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; 4-IODO-2,5-DIMETHOXYPHENYLISOPROPYLAMINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE DERIVATIVE; CALCIUM; ERGOT ALKALOID; MITOGEN ACTIVATED PROTEIN KINASE; RETINA S ANTIGEN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE;

ANIMAL CELL; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; EMBRYO; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION; VALVULAR HEART DISEASE; DOSE RESPONSE; DRUG EFFECTS; HEK293 CELL LINE; METABOLISM; PHOSPHORYLATION; RADIOASSAY; CELL STRAIN HEK293;

ADRENERGIC ALPHA-ANTAGONISTS; AMPHETAMINES; ARRESTINS; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOT ALKALOIDS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEK293 CELLS; HUMANS; PHENOXYBENZAMINE; PHOSPHORYLATION; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2B; SEROTONIN RECEPTOR AGONISTS; SIGNAL TRANSDUCTION;

EID: 84887865263     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.207670     Document Type: Article

References (58)

1. Battaglia R, Strolin Benedetti M, Mantegani S, Castelli M.G., Cocchiara G., and Dostert P (1993) Disposition and urinary metabolic pattern of cabergoline, a potent dopaminergic agonist, in rat, monkey and man. Xenobiotica 23: 1377-1389. (Pubitemid 24036135)
2. Blin O (2003) The pharmacokinetics of pergolide in Parkinson's disease. Curr Opin Neurol 16 (Suppl 1):S9-S12. (Pubitemid 38328108)
3. Boellner SW, Pennick M, Fiske K., Lyne A, and Shojaei A (2007) Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder. Pharmacotherapy 27: 1253-1262. (Pubitemid 47339123)
4. Boutin A, Allen MD, Geras-Raaka E, Huang W., Neumann S, and Gershengorn MC (2011) Thyrotropin receptor stimulates internalization-independent persistent phosphoinositide signaling. Mol Pharmacol 80:240-246.
5. Bredberg U, Eyjolfsdottir GS, Paalzow L, Tfelt-Hansen P, and Tfelt-Hansen V (1986) Pharmacokinetics of methysergide and its metabolite methylergometrine in man. Eur J Clin Pharmacol 30:75-77. (Pubitemid 16166987)
6. Caccia S, Conforti I, Duchier J., and Garattini S (1985) Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days. Eur J Clin Pharmacol 29:221-224. (Pubitemid 16246327)
7. Calebiro D, Nikolaev VO, Gagliani M.C., de Filippis T, Dees C, Tacchetti C., Persani L, and Lohse MJ (2009) Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol 7:e1000172.
8. Carchman SH, Crowe JT, Jr, and Wright GJ (1987) The bioavailability and pharmacokinetics of guanfacine after oral and intravenous administration to healthy volunteers. J Clin Pharmacol 27:762-767.
9. Charlton SJ and Vauquelin G (2010) Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br J Pharmacol 161: 1250-1265.
10. Colman E, Golden J, Roberts M., Egan A, Weaver J, and Rosebraugh C (2012) The FDA's assessment of two drugs for chronic weight management. N Engl J Med 367: 1577-1579.
11. de Hoon J.N., Poppe KA, Thijssen H.H., Struijker-Boudier HA, and Van Bortel LM (2001) Dihydroergotamine: discrepancy between arterial, arteriolar and pharmacokinetic data. Br J Clin Pharmacol 52:45-51. (Pubitemid 32862768)
12. de Marées H, Welzel D, de Marées A, Klotz U, Tiedjen KU, and Knaup G (1986) Relationship between the venoconstrictor activity of dihydroergotamine and its pharmacokinetics during acute and chronic oral dosing. Eur J Clin Pharmacol 30: 685-689. (Pubitemid 16018947)
13. Del Dotto P and Bonuccelli U (2003) Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet 42:633-645. (Pubitemid 36936528)
14. Derumeaux G, Ernande L, Serusclat A., Servan E, Bruckert E, Rousset H., Senn S, Van Gaal L, Picandet B, and Gavini F, et al.; REGULATE trial investigators (2012) Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus. PLoS ONE 7: e38273.
15. Dowling MR and Charlton SJ (2006) Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor. Br J Pharmacol 148:927-937. (Pubitemid 44543610)
16. Elangbam CS (2010) Drug-induced valvulopathy: an update. Toxicol Pathol 38: 837-848.
17. Fitzgerald LW, Burn TC, Brown B.S., Patterson JP, Corjay MH, Valentine PA, Sun J.H., Link JR, Abbaszade I, and Hollis JM, et al (2000) Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81. (Pubitemid 30033262)
18. Gu H, Luck S, Carroll P.V., Powrie J., and Chambers J (2011) Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clin Endocrinol (Oxf) 74:608-610.
19. Huang XP, Setola V, Yadav P.N., Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M., Doucette C, and Roth BL (2009) Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol 76:710-722.
20. Hutcheson JD, Setola V, Roth B.L., and Merryman WD (2011) Serotonin receptors and heart valve disease - it was meant 2B. Pharmacol Ther 132:146-157.
21. Irannejad R, Tomshine JC, Tomshine J.R., Chevalier M., Mahoney JP, Steyaert J, Rasmussen SG, Sunahara R.K., El-Samad H, and Huang B, et al (2013) Conformational biosensors reveal GPCR signalling from endosomes. Nature 495: 534-538.
22. Kaumann AJ and Levy FO (2006) 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 111:674-706. (Pubitemid 44118434)
23. Lafeber M, Stades AM, Valk G.D., Cramer MJ, Teding van Berkhout F, and Zelissen PM (2010) Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur J Endocrinol 162:667-675.
24. Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen P.F., and Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27: 600-611. (Pubitemid 15010691)
25. Loke YK, Derry S, and Pritchard-Copley A (2002) Appetite suppressants and valvular heart disease - a systematic review. BMC Clin Pharmacol 2:6.
26. MaassenVanDenBrink A, Reekers M, Bax W.A., Ferrari MD, and Saxena PR (1998) Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 98:25-30. (Pubitemid 28312075)
27. Maurer G and Frick W (1984a) Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol 26:463-470. (Pubitemid 14149126)
28. Maurer G and Frick W (1984b) Elucidation of the structure and receptor binding studies of the major primary, metabolite of dihydroergotamine in man. Eur J Clin Pharmacol 26:463-470. (Pubitemid 14149126)
29. Millan MJ, Maiofiss L, Cussac D., Audinot V, Boutin JA, and Newman-Tancredi A (2002) Differential actions of antiparkinson agents at multiple classes of mono-aminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 303: 791-804. (Pubitemid 35231256)
30. Morelle A, Bensadon A-C, and Marie E (2011) Enquête sur le Mediator. Inspection générale des affaires sociales. http://www.ladocumentationfrancaise.fr/rapports-publics/114000028/index.shtml.
31. Motulsky HJ and Mahan LC (1984) The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol 25:1-9. (Pubitemid 14223246)
32. Müller-Schweinitzer E (1980) In vitro studies on the duration of action of di-hydroergotamine. Int J Clin Pharmacol Ther Toxicol 18:88-91. (Pubitemid 10169024)
33. Müller-Schweinitzer E (1984) Pharmacological actions of the main metabolites of dihydroergotamine. Eur J Clin Pharmacol 26:699-705. (Pubitemid 14074642)
34. Mullershausen F, Zecri F, Cetin C., Billich A, Guerini D, and Seuwen K (2009) Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 5:428-434.
35. Neumann S, Geras-Raaka E, Marcus-Samuels B, and Gershengorn MC (2010) Persistent cAMP signaling by thyrotropin (TSH) receptors is not dependent on in-ternalization. FASEB J 24:3992-3999.
36. Ostergaard JR, Mikkelsen E, and Voldby B (1981) Effects of 5-hydroxytrypta-mine and ergotamine on human superficial temporal artery. Cephalalgia 1: 223-228. (Pubitemid 12191437)
37. Peyronneau MA, Delaforge M, Riviere R., Renaud JP, and Mansuy D (1994) High affinity of ergopeptides for cytochromes P450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine. Eur J Biochem 223:947-956. (Pubitemid 24263179)
38. Richman JG, Kanemitsu-Parks M, Gaidarov I., Cameron JS, Griffin P, Zheng H, Guerra N.C., Cham L., Maciejewski-Lenoir D, and Behan DP, et al (2007) Nicotinic acid receptor agonists differentially activate downstream effectors. J Biol Chem 282:18028-18036. (Pubitemid 47100250)
39. Rothman RB and Baumann MH (2009) Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 8:317-329.
40. Rothman RB, Baumann MH, Savage J.E., Rauser L., McBride A, Hufeisen SJ, and Roth BL (2000) Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102:2836-2841.
41. Rubin A, Lemberger L, and Dhahir P (1981) Physiologic disposition of pergolide. Clin Pharmacol Ther 30:258-265. (Pubitemid 12149148)
42. Sachdev M, Miller WC, Ryan T, and Jollis JG (2002) Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 144:1065-1073. (Pubitemid 36026921)
43. Saper JR and Silberstein S (2006) Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 46 (Suppl 4):S171-S181. (Pubitemid 44656902)
44. Schade R, Andersohn F, Suissa S., Haverkamp W, and Garbe E (2007) Dopa-mine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356: 29-38. (Pubitemid 46041751)
45. Schöning C., Flieger M, and Pertz HH (2001) Complex interaction of ergovaline with 5-HT2A, 5-HT1B/1D, and alpha1 receptors in isolated arteries of rat and guinea pig. J Anim Sci 79:2202-2209. (Pubitemid 33721472)
46. Schran HF, Schwarz HJ, Talbot K.C., and Loeffler LJ (1979) Specific radioimmuno-assay of ergot peptide alkaloids in plasma. Clin Chem 25:1928-1933. (Pubitemid 10170181)
47. Schran HF and Tse FL (1985) Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. Int J Clin Pharmacol Ther Toxicol 23: 1-4. (Pubitemid 15195824)
48. Sibley DR and Creese I (1983) Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors. Mol Pharmacol 23:585-593. (Pubitemid 13089774)
49. Silberstein SD (1997) The pharmacology of ergotamine and dihydroergotamine. Headache 37 (Suppl 1):S15-S25.
50. Spinelli R, Fracasso C, Guiso G., Garattini S, and Caccia S (1988) Disposition of (-)-fenfluramine and its active metabolite, (-)-norfenfluramine in rat: a single dose-proportionality study. Xenobiotica 18:573-584.
51. Steffensen C, Maegbaek ML, Laurberg P, Andersen M., Kistorp CM, Norrelund H, Sørensen HT, and Jorgensen JO (2012) Heart valve disease among patients with hyperprolactinemia: a nationwide population-based cohort study. J Clin Endo-crinol Metab 97:1629-1634.
52. Tan T, Cabrita IZ, Hensman D, Grogono J., Dhillo WS, Baynes KC, Eliahoo J, Meeran K., Robinson S, and Nihoyannopoulos P, et al (2010) Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf) 73:369-374.
53. Tfelt-Hansen P and Paalzow L (1985) Intramuscular ergotamine: plasma levels and dynamic activity. Clin Pharmacol Ther 37:29-35. (Pubitemid 16225163)
54. Vallette S, Serri K, and Serri O (2010) Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? Expert Rev Cardiovasc Ther 8: 49-54.
55. Wacker D, Wang C, Katritch V., Han GW, Huang XP, Vardy E, McCorvy J.D., Jiang Y., Chu M, and Siu FY, et al (2013) Structural features for functional selectivity at serotonin receptors. Science 340:615-619.
56. Wang C, Jiang Y, Ma J., Wu H, Wacker D, Katritch V., Han GW, Liu W, Huang XP, and Vardy E, et al. (2013) Structural basis for molecular recognition at serotonin receptors. Science 340:610-614.
57. Werthmann RC, Volpe S, Lohse M.J., and Calebiro D (2012) Persistent cAMP signaling by internalized TSH receptors occurs in thyroid but not in HEK293 cells. FASEB J 26:2043-2048.
58. Zanettini R, Antonini A, Gatto G., Gentile R, Tesei S, and Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:39-46. (Pubitemid 46041752)